Single-tracer Multiparametric PET Imaging

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

February 14, 2024

Primary Completion Date

August 31, 2028

Study Completion Date

August 31, 2033

Conditions
Healthy SubjectsCardiovascular Disease
Interventions
DRUG

18F-FDG

Each subject will undergo a dynamic 18F-FDG PET/CT scan (this drug is FDA approved) and a dynamic 11C-butanol PET/CT scan (this drug is under an IND) on the EXPLORER total-body PET/CT system. The two scans will be performed on the same day or within a period of up to two weeks depending on subject, imaging agent and scanner availability.

DRUG

11C-butanol

Each subject will undergo a dynamic 18F-FDG PET/CT scan (this drug is FDA approved) and a dynamic 11C-butanol PET/CT scan (this drug is under an IND) on the EXPLORER total-body PET/CT system. The two scans will be performed on the same day or within a period of up to two weeks depending on subject, imaging agent and scanner availability.

Trial Locations (1)

95816

RECRUITING

UC Davis EXPLORER Molecular Imaging Center, Sacramento

All Listed Sponsors
collaborator

National Institute for Biomedical Imaging and Bioengineering (NIBIB)

NIH

lead

University of California, Davis

OTHER